Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fortis

Showing results (1-10 of 20) with videos related to

Pageof 2
Sort By:
The Prostate|May 1, 1996
Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatmentM Maffezzini, A Simonato, C Fortis
Journal of Biological Regulators and Homeostatic Agents|May 11, 2002
Natural killer cell function in HIV-1 infected patientsC Fortis, S Tasca, B Capiluppi, et al.
Anticancer Research|July 1, 1996
Cell activation and death (apoptosis) induced by IL-2: ultrastructural evidenceE Capelli, S Barni, R Vaccarone, et al.
British Journal of Cancer|November 1, 1990
LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytesM Ferrarini, E Ferrero, C Fortis, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1994
Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapyE Clementi, E Bucci, G Citterio, et al.
Journal of Surgical Oncology|January 13, 1998
Radical oncologic surgery affects the circulatory levels of interleukin 10L Gianotti, C Fortis, M Braga, et al.
The Journal of Surgical Research|May 1, 1996
Thymopentin modulates Th1 and Th2 cytokine response and host survival in experimental injuryM Braga, L Gianotti, O Gentilini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1979
Study on the turnover of the receptor for the third component of complement on human lymphoid cellsV E Rosso di San Secondo, P L Meroni, C Fortis, et al.
Clinical Immunology and Immunopathology|August 1, 1995
Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapyC Fortis, L Galli, G Consogno, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 1987
Selection and characterization of T-cell variants lacking molecules involved in T-cell activation (T3 T-cell receptor, T44, and T11): analysis of the functional relationship among different pathways of activationA Moretta, A Poggi, D Olive, et al.
Pageof 2

Showing results (1-10 of 20) with videos related to

Sort By:
Pageof 2
The Prostate|May 1, 1996
Salvage immunotherapy with subcutaneous recombinant interleukin 2 (rIL-2) and alpha-interferon (A-IFN) for stage D3 prostate carcinoma failing second-line hormonal treatmentM Maffezzini, A Simonato, C Fortis
Journal of Biological Regulators and Homeostatic Agents|May 11, 2002
Natural killer cell function in HIV-1 infected patientsC Fortis, S Tasca, B Capiluppi, et al.
Anticancer Research|July 1, 1996
Cell activation and death (apoptosis) induced by IL-2: ultrastructural evidenceE Capelli, S Barni, R Vaccarone, et al.
British Journal of Cancer|November 1, 1990
LAK1 antigen defines two distinct subsets among human tumour infiltrating lymphocytesM Ferrarini, E Ferrero, C Fortis, et al.
Cancer Immunology, Immunotherapy : CII|September 1, 1994
Reversible anergy in circulating lymphocytes of cancer patients during interleukin-2 therapyE Clementi, E Bucci, G Citterio, et al.
Journal of Surgical Oncology|January 13, 1998
Radical oncologic surgery affects the circulatory levels of interleukin 10L Gianotti, C Fortis, M Braga, et al.
The Journal of Surgical Research|May 1, 1996
Thymopentin modulates Th1 and Th2 cytokine response and host survival in experimental injuryM Braga, L Gianotti, O Gentilini, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 1, 1979
Study on the turnover of the receptor for the third component of complement on human lymphoid cellsV E Rosso di San Secondo, P L Meroni, C Fortis, et al.
Clinical Immunology and Immunopathology|August 1, 1995
Serum levels of soluble cell adhesion molecules (ICAM-1, VCAM-1, E-selectin) and of cytokine TNF-alpha increase during interleukin-2 therapyC Fortis, L Galli, G Consogno, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 1987
Selection and characterization of T-cell variants lacking molecules involved in T-cell activation (T3 T-cell receptor, T44, and T11): analysis of the functional relationship among different pathways of activationA Moretta, A Poggi, D Olive, et al.
Pageof 2